GlassScriptPhysician profile
Jeffrey M Boyd
NPI 1770076176
$3,804.44
in general payments reported to CMS, 2019-2025
19 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.70 · 2022: $22.24 · 2023: $411 · 2024: $1,648 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,465 · Travel and Lodging: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,465.22 |
| Travel and Lodging | $289.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,135.39 | 2023-2025 | Wavewriter Alpha Prime 16, Intracept Rf Probe, General - Pain Management |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $502.01 | 2024-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $474.23 | 2023-2025 | Belbuca, Xtampza |
| Curonix LLC | $367.67 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Saluda Medical Americas, INC. | $230.36 | 2025 | Evoke |
| Abbvie INC. | $228.93 | 2022-2025 | Botox |
| Scilex Pharmaceuticals INC. | $208.49 | 2023-2025 | Ztlido |
| Vertos Medical, INC. | $148.73 | 2024 | Mild Device Kit |
| Stryker Corporation | $109.09 | 2024 | Mild Device Kit |
| Averitas Pharma INC. | $108.06 | 2023-2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $63.89 | 2025 | |
| Valinor Pharma, LLC | $55.51 | 2024 | Movantik |
| Medtronic, INC. | $40.66 | 2023 | Intellis Adaptivestim |
| Foundation Fusion Solutions, LLC | $32.61 | 2025 | |
| Coloplast Corp | $27.70 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21.14 | 2023 | |
| Optinose US, INC. | $20.06 | 2024 | |
| Mml US, INC. | $17.10 | 2025 | Reactiv8 |
| Relievant Medsystems, INC. | $12.81 | 2023 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.